Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

"Stress and the aging brain: the interplay between genetic susceptibility, aging and psychosocial stress on early symptoms of dementia"

STAGED

As the population is growing older, the risk for dementia increases. The complexity of dementia calls for a multidisciplinary approach; in this project I will combine the research fields of Epidemiology, Genetics, Psychology and Cognitive Neuroscience. It is crucial to identify persons at risk for developing dementia, as possible treatment...

Funding Programme
Start Date
End Date
Total Funding
€ 136 064
European Countries Involved

22nd Alzheimer Europe Conference: Changing perceptions, practice and policy

The Commission Communication on a European initiative on Alzheimer`s disease ingled out four main areas for greater EU collaboration:

  • Acting early to diagnose dementia,
  • A shared European effort in research,
  • National solidarity and exchange of best care practices,
  • Respecting the rights of people with dementia.
Funding Programme
Start Date
End Date
Total Funding
€ 60 000
European Countries Involved

23rd AE Conference: Living well in a dementia friendly society

The Conference will organise an exchange of information and best practices on key aspects of the European Innovation Partnership on Active and Healthy Ageing in the fields of Integrated care, Prevention, Dementia friendly society and Innovative solutions.
Funding Programme
Start Date
End Date
Total Funding
€ 80 000
European Countries Involved

24th AE Conference

The Conference is fully in line with the areas singled out in the Commission Communication on a European initiative on Alzheimer`s disease for greater EU collaboration, namely

1. Acting early to diagnose dementia,

2. A shared European effort in research,

3. National solidarity and exchange of best care practices,

4. Respecting the...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

ArrestAD

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure...
Funding Programme
Start Date
End Date
Total Funding
€ 3 991 096
European Countries Involved

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

BRIGHT

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A blood based biomarker identifying early Alzheimer Disease's pathology

VERDAD

Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in...
Funding Programme
Start Date
End Date
Total Funding
€ 3 365 416
European Countries Involved

A Drug Discovery and Target Identification Screening Platform for Age-Associated Neurodegenerative Disorders

NeuronAgeScreen

Battling human neurodegenerative pathologies, and their pervasive societal impact, is a global multi-billion Euro enterprise. Ageing is universally associated with marked decrease of neuronal function and higher susceptibility to neurodegeneration. In human populations, this is manifested as an ever-increasing prevalence of devastating...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

A European DNA bank for deciphering the missing heritability of Alzheimer’s disease

EADB

Understanding the genetics of Alzheimer's disease (AD) is one of the best ways of improving our knowledge of the disease's underlying pathophysiological processes. Indeed, genetic factors account for up to 70% of the attributable risk in common forms of AD. The advent of genomic approaches has led to the characterization of 26 genetic determinants...

Funding Programme
Start Date
End Date
Total Funding
€ 3 644 713
European Countries Involved

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease

NILVAD

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even...
Funding Programme
Start Date
End Date
Total Funding
€ 7 916 016
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).